Overview
The study aim to evaluate the efficacy of cord blood eye drops in the healing of the damaged corneal epithelium.
Description
Patients undergoing treatment with EGFR inhibitor for lung cancer might develop corneal damage.
The study aims to evaluate the healing of corneal epithelium by administering cord blood eye drops for one month.
Eligibility
Inclusion Criteria:
- age over 18 years
- oncology and advanced cancer patients who have EGFr mutation and who require treatment with antiEGFr drugs
- signing of informed consent
Exclusion Criteria:
- Patients who are unable to store/administer the CSCO independently, or with the help of care-givers.